NewsletterNewsletter | July 202022 Jul 20200Patrys is pleased to share its latest Newsletter, published July 2020. Key highlights: Letter From Our CEO Media and Analyst…
News UpdateBioshares | July 202020 Jul 20200Patrys was featured in the latest issue of BioShares in an article titled, “Patrys – Synthetic Lethality to Kill Cancer…
MediaHealth Kick Podcast | With Tim Boreham7 May 20200Health and Biotech expert, Tim Boreham, interviewed Patrys CEO and MD, Dr James Campbell, for the Health Kick Podcast. Listen…
News UpdateArticle | DDR therapeutics22 Apr 20200Patrys CEO and MD, Dr James Campbell, has written an article titled “DDR therapeutics and synthetic lethality – a precise…
News UpdateArticle | AstraZeneca20 Apr 20200AstraZeneca has published an article titled, “Combatting cancer by exploiting the DNA Damage Response.” Read it here.
NewsletterNewsletter | June 20191 Jun 20190Patrys is pleased to share its latest Newsletter, published June 2019. Key highlights: Letter from our CEO Progress with PAT-DX1…
News UpdateBioshares | October 201819 Oct 20180Patrys was featured in the latest issue of BioShares in an article titled, “Patrys Selects Indications for Unique Cancer Treatment…
MediaMedia | Biopharma Deal Makers10 Sep 20180Biopharma Deal Makers has published an article titled, “Nuclear-penetrating DNA binding antibodies as cancer therapies.” Read it here.
NewsletterNewsletter | May 201810 May 20180Patrys is pleased to share its latest Newsletter, published May 2018. Key highlights: Letter from our CEO Update on deoxymabs…
MediaMedia | Stockhead14 Sep 20170Stockhead has published an article titled, “Aussie cancer drug developer jumps 400pc after human tissue tests” Read it here.